SAN DIEGO, May 19 /PRNewswire/ -- Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of therapeutic oxygen transport agents today announced that it has completed enrollment in the second Phase III trial of its lead product, Hemospan(R).
Sangart expects the top line results from this trial to be available in the second half of 2008.
The 370-patient randomized, double-blind, controlled Phase III study was conducted at 18 clinical sites in six European countries. Together with another Phase III study completed in March, the trials were designed to evaluate the safety and efficacy of Hemospan for preventing and treating hemodynamic instability, particularly hypotension, or low blood pressure, during primary hip replacement surgery.
Dr. Robert Winslow, Chairman, President and CEO of Sangart, commented, "The completed enrollment in this second Phase III trial represents another significant milestone for Sangart as we advance the development of Hemospan."
No similar oxygen transport agents are currently on the market in Europe or the United States. Extensive preclinical efficacy studies and earlier clinical trials indicate that Hemospan's novel oxygen delivery mechanism has the potential to enhance oxygenation of ischemic tissues and may provide a safe and effective alternative to blood transfusion, especially when blood is not immediately available.
Sangart is a privately held San Diego-based biopharmaceutical company focused on the research, development and commercialization of medical products designed for use as therapeutic oxygen transport agents and potential alternatives to blood transfusions.
Dr. Robert Winslow, a world-renowned authority in the field of oxygen
transport, founded Sangart in 1998. In the two decades prior to founding
Sangart, Dr. Winslow and his colleagues studied and defined mechanisms of
oxygen transport by cell-f
|SOURCE Sangart, Inc.|
Copyright©2008 PR Newswire.
All rights reserved